Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 355

1.

Reply.

Campochiaro PA, Maass KF, Singh N, Barteselli G.

Ophthalmology. 2019 Nov;126(11):e88-e89. doi: 10.1016/j.ophtha.2019.06.020. No abstract available.

PMID:
31635711
2.

A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular Neovascularization.

Wojnarowicz PM, Lima E Silva R, Ohnaka M, Lee SB, Chin Y, Kulukian A, Chang SH, Desai B, Garcia Escolano M, Shah R, Garcia-Cao M, Xu S, Kadam R, Goldgur Y, Miller MA, Ouerfelli O, Yang G, Arakawa T, Albanese SK, Garland WA, Stoller G, Chaudhary J, Norton L, Soni RK, Philip J, Hendrickson RC, Iavarone A, Dannenberg AJ, Chodera JD, Pavletich N, Lasorella A, Campochiaro PA, Benezra R.

Cell Rep. 2019 Oct 1;29(1):62-75.e7. doi: 10.1016/j.celrep.2019.08.073.

3.

Different Factors Associated with 2-Year Outcomes in Patients with Branch versus Central Retinal Vein Occlusion Treated with Ranibizumab.

Sophie R, Wang PW, Channa R, Quezada-Ruiz C, Clark A, Campochiaro PA.

Ophthalmology. 2019 Jul 23. pii: S0161-6420(19)30590-1. doi: 10.1016/j.ophtha.2019.07.018. [Epub ahead of print]

PMID:
31543350
4.

AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression.

Ding K, Shen J, Hafiz Z, Hackett SF, Silva RLE, Khan M, Lorenc VE, Chen D, Chadha R, Zhang M, Van Everen S, Buss N, Fiscella M, Danos O, Campochiaro PA.

J Clin Invest. 2019 Aug 13;130:4901-4911. doi: 10.1172/JCI129085.

5.

Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization.

Kim J, Lima E Silva R, Shmueli RB, Mirando AC, Tzeng SY, Pandey NB, Ben-Akiva E, Popel AS, Campochiaro PA, Green JJ.

Acta Biomater. 2019 Oct 1;97:451-460. doi: 10.1016/j.actbio.2019.07.054. Epub 2019 Jul 30.

PMID:
31374338
6.

Low risk to retina from sustained suppression of VEGF.

Campochiaro PA.

J Clin Invest. 2019 Jun 24;129(8):3029-3031. doi: 10.1172/JCI129861. eCollection 2019 Jun 24. No abstract available.

7.

Progression of Retinitis Pigmentosa as Measured on Microperimetry: The PREP-1 Study.

Iftikhar M, Kherani S, Kaur R, Lemus M, Nefalar A, Usmani B, Junaid N, Campochiaro PA, Scholl HPN, Shah SM.

Ophthalmol Retina. 2018 May;2(5):502-507. doi: 10.1016/j.oret.2017.09.008. Epub 2017 Nov 9.

PMID:
31047333
8.

Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study.

Campochiaro PA, Wykoff CC, Brown DM, Boyer DS, Barakat M, Taraborelli D, Noronha G; Tanzanite Study Group.

Ophthalmol Retina. 2018 Apr;2(4):320-328. doi: 10.1016/j.oret.2017.07.013. Epub 2017 Sep 29.

PMID:
31047241
9.

Loss of Peak Vision in Retinal Vein Occlusion Patients Treated for Macular Edema.

Iftikhar M, Mir TA, Hafiz G, Zimmer-Galler I, Scott AW, Solomon SD, Sodhi A, Wenick AS, Meyerle C, Jiramongkolchai K, Liu TYA, Arevalo JF, Singh M, Kherani S, Handa JT, Campochiaro PA.

Am J Ophthalmol. 2019 Sep;205:17-26. doi: 10.1016/j.ajo.2019.03.029. Epub 2019 Apr 4.

PMID:
30954469
10.

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.

Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adamis AP, Bantseev V, Chiang Y, Ehrlich JS, Erickson S, Hanley WD, Horvath J, Maass KF, Singh N, Tang F, Barteselli G.

Ophthalmology. 2019 Aug;126(8):1141-1154. doi: 10.1016/j.ophtha.2019.03.036. Epub 2019 Apr 1.

11.

Classification of disease severity in retinitis pigmentosa.

Iftikhar M, Lemus M, Usmani B, Campochiaro PA, Sahel JA, Scholl HPN, Shah SMA.

Br J Ophthalmol. 2019 Nov;103(11):1595-1599. doi: 10.1136/bjophthalmol-2018-313669. Epub 2019 Jan 31.

PMID:
30705041
12.

A collagen IV-derived peptide disrupts α5β1 integrin and potentiates Ang2/Tie2 signaling.

Mirando AC, Shen J, Silva RLE, Chu Z, Sass NC, Lorenc VE, Green JJ, Campochiaro PA, Popel AS, Pandey NB.

JCI Insight. 2019 Feb 21;4(4). pii: 122043. doi: 10.1172/jci.insight.122043. eCollection 2019 Feb 21.

13.

Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection.

Zhang Y, Bazzazi H, Lima E Silva R, Pandey NB, Green JJ, Campochiaro PA, Popel AS.

Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):5266-5276. doi: 10.1167/iovs.17-23632.

14.

Metipranolol promotes structure and function of retinal photoreceptors in the rd10 mouse model of human retinitis pigmentosa.

Kanan Y, Khan M, Lorenc VE, Long D, Chadha R, Sciamanna J, Green K, Campochiaro PA.

J Neurochem. 2019 Jan;148(2):307-318. doi: 10.1111/jnc.14613. Epub 2018 Dec 3.

PMID:
30315650
15.

VEGF/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models.

Long D, Kanan Y, Shen J, Hackett SF, Liu Y, Hafiz Z, Khan M, Lu L, Campochiaro PA.

JCI Insight. 2018 May 17;3(10). pii: 120231. doi: 10.1172/jci.insight.120231. eCollection 2018 May 17.

16.

Mousetap, a Novel Technique to Collect Uncontaminated Vitreous or Aqueous and Expand Usefulness of Mouse Models.

Fortmann SD, Lorenc VE, Shen J, Hackett SF, Campochiaro PA.

Sci Rep. 2018 Apr 23;8(1):6371. doi: 10.1038/s41598-018-24197-2.

17.

Shortest Distance From Fovea to Subfoveal Hemorrhage Border Is Important in Patients With Neovascular Age-related Macular Degeneration.

Kherani S, Scott AW, Wenick AS, Zimmer-Galler I, Brady CJ, Sodhi A, Meyerle C, Solomon SD, Shaukat R, Channa R, Adeyemo O, Handa JT, Wang J, Campochiaro PA.

Am J Ophthalmol. 2018 May;189:86-95. doi: 10.1016/j.ajo.2018.02.015. Epub 2018 Feb 28.

PMID:
29499174
18.

AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration.

Liu Y, Fortmann SD, Shen J, Wielechowski E, Tretiakova A, Yoo S, Kozarsky K, Wang J, Wilson JM, Campochiaro PA.

Mol Ther. 2018 Feb 7;26(2):542-549. doi: 10.1016/j.ymthe.2017.12.002. Epub 2017 Dec 8.

19.

Ocular gene therapy for neovascular AMD: a new era? - Authors' reply.

Campochiaro PA, Heier JS, Kherani S, Le-Halpere A, Scaria A.

Lancet. 2017 Nov 11;390(10108):2140. doi: 10.1016/S0140-6736(17)32424-8. Epub 2017 Nov 9. No abstract available.

PMID:
29143750
20.

The mechanism of cone cell death in Retinitis Pigmentosa.

Campochiaro PA, Mir TA.

Prog Retin Eye Res. 2018 Jan;62:24-37. doi: 10.1016/j.preteyeres.2017.08.004. Epub 2017 Sep 27. Review.

PMID:
28962928
21.

Reply.

Campochiaro PA, Mir TA, Han YS, Kherani S, Hafiz G, Krispel C, Liu TYA, Wang J, Scott AW, Zimmer-Galler I.

Am J Ophthalmol. 2017 Nov;183:163-164. doi: 10.1016/j.ajo.2017.09.006. Epub 2017 Sep 20. No abstract available.

PMID:
28941645
22.

Reversible retinal vessel closure from VEGF-induced leukocyte plugging.

Liu Y, Shen J, Fortmann SD, Wang J, Vestweber D, Campochiaro PA.

JCI Insight. 2017 Sep 21;2(18). pii: 95530. doi: 10.1172/jci.insight.95530. eCollection 2017 Sep 21.

23.

Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial.

Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, Delacono C, Purvis A, Richards S, Le-Halpere A, Connelly J, Wadsworth SC, Varona R, Buggage R, Scaria A, Campochiaro PA.

Lancet. 2017 Jul 1;390(10089):50-61. doi: 10.1016/S0140-6736(17)30979-0. Epub 2017 May 17. Erratum in: Lancet. 2017 Jul 1;390(10089):28.

PMID:
28526489
24.

Increased Frequency of Topical Steroids Provides Benefit in Patients With Recalcitrant Postsurgical Macular Edema.

Campochiaro PA, Han YS, Mir TA, Kherani S, Hafiz G, Krispel C, Liu TYA, Wang J, Scott AW, Zimmer-Galler I.

Am J Ophthalmol. 2017 Jun;178:163-175. doi: 10.1016/j.ajo.2017.03.033. Epub 2017 Apr 7.

PMID:
28392176
25.

Systematic Functional Testing of Rare Variants: Contributions of CFI to Age-Related Macular Degeneration.

Tan PL, Garrett ME, Willer JR, Campochiaro PA, Campochiaro B, Zack DJ, Ashley-Koch AE, Katsanis N.

Invest Ophthalmol Vis Sci. 2017 Mar 1;58(3):1570-1576. doi: 10.1167/iovs.16-20867.

26.

The Nicotinic Cholinergic Pathway Contributes to Retinal Neovascularization in a Mouse Model of Retinopathy of Prematurity.

Hackett SF, Seidel C, Abraham S, Chadha R, Fortmann SD, Campochiaro PA, Cooke JP.

Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):1296-1303. doi: 10.1167/iovs.16-20670.

27.

Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.

Silva RLE, Kanan Y, Mirando AC, Kim J, Shmueli RB, Lorenc VE, Fortmann SD, Sciamanna J, Pandey NB, Green JJ, Popel AS, Campochiaro PA.

Sci Transl Med. 2017 Jan 18;9(373). pii: eaai8030. doi: 10.1126/scitranslmed.aai8030.

28.

Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.

Wykoff CC, Chakravarthy U, Campochiaro PA, Bailey C, Green K, Cunha-Vaz J.

Ophthalmology. 2017 Apr;124(4):440-449. doi: 10.1016/j.ophtha.2016.11.034. Epub 2017 Jan 9.

PMID:
28081945
29.

The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization.

Zeng M, Shen J, Liu Y, Lu LY, Ding K, Fortmann SD, Khan M, Wang J, Hackett SF, Semenza GL, Campochiaro PA.

J Mol Med (Berl). 2017 Apr;95(4):417-429. doi: 10.1007/s00109-016-1498-9. Epub 2016 Dec 21.

30.

Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema.

Campochiaro PA, Peters KG.

Curr Diab Rep. 2016 Dec;16(12):126. Review.

PMID:
27778249
31.

Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study.

Campochiaro PA, Lauer AK, Sohn EH, Mir TA, Naylor S, Anderton MC, Kelleher M, Harrop R, Ellis S, Mitrophanous KA.

Hum Gene Ther. 2017 Jan;28(1):99-111. doi: 10.1089/hum.2016.117. Epub 2016 Sep 26.

32.

Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study.

Sepah YJ, Sadiq MA, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus D, Halperin L, Hassan M, Campochiaro PA, Nguyen QD, Do DV; READ-3 Study Group.

Ophthalmology. 2016 Dec;123(12):2581-2587. doi: 10.1016/j.ophtha.2016.08.040. Epub 2016 Oct 1.

PMID:
27707550
33.

Reply.

Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA.

Ophthalmology. 2016 Oct;123(10):e60-1. doi: 10.1016/j.ophtha.2016.03.020. No abstract available.

PMID:
27664917
34.

Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease: From Bench to Bedside.

Campochiaro PA, Aiello LP, Rosenfeld PJ.

Ophthalmology. 2016 Oct;123(10S):S78-S88. doi: 10.1016/j.ophtha.2016.04.056.

PMID:
27664289
35.

Reply.

Campochiaro PA, Hafiz G, Mir TA, Scott AW, Zimmer-Galler I, Shah SM, Wenick AS, Brady CJ, Han I, He L, Channa R, Poon D, Meyerle C, Aronow MB, Sodhi A, Handa JT, Kherani S, Han Y, Sophie R, Wang G, Qian J.

Am J Ophthalmol. 2016 Oct;170:245-246. doi: 10.1016/j.ajo.2016.07.014. Epub 2016 Aug 22. No abstract available.

PMID:
27561424
36.

Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.

Campochiaro PA, Khanani A, Singer M, Patel S, Boyer D, Dugel P, Kherani S, Withers B, Gambino L, Peters K, Brigell M; TIME-2 Study Group.

Ophthalmology. 2016 Aug;123(8):1722-1730. doi: 10.1016/j.ophtha.2016.04.025. Epub 2016 May 26.

PMID:
27236272
37.

Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials.

Parrish RK 2nd, Campochiaro PA, Pearson PA, Green K, Traverso CE; FAME Study Group.

Ophthalmic Surg Lasers Imaging Retina. 2016 May 1;47(5):426-35. doi: 10.3928/23258160-20160419-05.

PMID:
27183546
38.

Pro-permeability Factors in Diabetic Macular Edema; the Diabetic Macular Edema Treated With Ozurdex Trial.

Campochiaro PA, Hafiz G, Mir TA, Scott AW, Zimmer-Galler I, Shah SM, Wenick AS, Brady CJ, Han I, He L, Channa R, Poon D, Meyerle C, Aronow MB, Sodhi A, Handa JT, Kherani S, Han Y, Sophie R, Wang G, Qian J.

Am J Ophthalmol. 2016 Aug;168:13-23. doi: 10.1016/j.ajo.2016.04.017. Epub 2016 Apr 27.

39.

Reply.

Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I, Sodhi A, Duh E, Ying HS, Wenick AS, Shah SM, Do DV, Nguyen QD, Kherani S, Sophie R.

Ophthalmology. 2016 May;123(5):e33-4. doi: 10.1016/j.ophtha.2015.11.024. No abstract available.

PMID:
27107360
40.

Reply.

Sophie R, Lu N, Campochiaro PA.

Ophthalmology. 2016 Feb;123(2):e12-3. doi: 10.1016/j.ophtha.2015.08.003. No abstract available.

PMID:
26802714
41.

Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in Retinal Vein Occlusion.

Mir TA, Kherani S, Hafiz G, Scott AW, Zimmer-Galler I, Wenick AS, Solomon S, Han I, Poon D, He L, Shah SM, Brady CJ, Meyerle C, Sodhi A, Linz MO, Sophie R, Campochiaro PA.

Ophthalmology. 2016 Mar;123(3):625-34.e1. doi: 10.1016/j.ophtha.2015.10.030. Epub 2015 Dec 19.

42.

Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.

Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA.

Ophthalmology. 2016 Feb;123(2):330-6. doi: 10.1016/j.ophtha.2015.09.035. Epub 2015 Oct 30.

PMID:
26522708
43.

Reply.

Campochiaro PA, Hafiz G, Mir TA, Scott AW, Sophie R, Shah SM, Ying HS, Lu L, Chen C, Campbell JP, Kherani S, Zimmer-Galler I, Wenick A, Han I, Paulus Y, Sodhi A, Wang G, Qian J.

Am J Ophthalmol. 2016 Jan;161:216-7. doi: 10.1016/j.ajo.2015.09.034. Epub 2015 Oct 23. No abstract available.

PMID:
26482397
44.

Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose).

Do DV, Sepah YJ, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus DM, Halperin L, Sadiq MA, Rajagopalan N, Campochiaro PA, Nguyen QD; READ-3 Study Group.

Eye (Lond). 2015 Dec;29(12):1538-44. doi: 10.1038/eye.2015.142. Epub 2015 Jul 31.

45.

Molecular pathogenesis of retinal and choroidal vascular diseases.

Campochiaro PA.

Prog Retin Eye Res. 2015 Nov;49:67-81. doi: 10.1016/j.preteyeres.2015.06.002. Epub 2015 Jun 23. Review.

46.

Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial.

Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I, Sodhi A, Duh E, Ying H, Wenick A, Shah SM, Do DV, Nguyen QD, Kherani S, Sophie R.

Ophthalmology. 2015 Jul;122(7):1426-37. doi: 10.1016/j.ophtha.2015.04.006. Epub 2015 May 9.

PMID:
25972260
47.

Pro-Permeability Factors After Dexamethasone Implant in Retinal Vein Occlusion; the Ozurdex for Retinal Vein Occlusion (ORVO) Study.

Campochiaro PA, Hafiz G, Mir TA, Scott AW, Sophie R, Shah SM, Ying HS, Lu L, Chen C, Campbell JP, Kherani S, Zimmer-Galler I, Wenick A, Han I, Paulus Y, Sodhi A, Wang G, Qian J.

Am J Ophthalmol. 2015 Aug;160(2):313-321.e19. doi: 10.1016/j.ajo.2015.04.025. Epub 2015 Apr 20.

48.

Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab.

Sophie R, Lu N, Campochiaro PA.

Ophthalmology. 2015 Jul;122(7):1395-401. doi: 10.1016/j.ophtha.2015.02.036. Epub 2015 Apr 11.

49.

Is There Excess Oxidative Stress and Damage in Eyes of Patients with Retinitis Pigmentosa?

Campochiaro PA, Strauss RW, Lu L, Hafiz G, Wolfson Y, Shah SM, Sophie R, Mir TA, Scholl HP.

Antioxid Redox Signal. 2015 Sep 1;23(7):643-8. doi: 10.1089/ars.2015.6327. Epub 2015 Apr 30.

50.

Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2.

Campochiaro PA, Sophie R, Tolentino M, Miller DM, Browning D, Boyer DS, Heier JS, Gambino L, Withers B, Brigell M, Peters K.

Ophthalmology. 2015 Mar;122(3):545-54. doi: 10.1016/j.ophtha.2014.09.023. Epub 2014 Nov 12.

PMID:
25439435

Supplemental Content

Loading ...
Support Center